GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cryomass Technologies Inc (OTCPK:CRYM) » Definitions » Debt-to-EBITDA

Cryomass Technologies (Cryomass Technologies) Debt-to-EBITDA : -0.51 (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Cryomass Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cryomass Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.23 Mil. Cryomass Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.43 Mil. Cryomass Technologies's annualized EBITDA for the quarter that ended in Sep. 2023 was $-5.26 Mil. Cryomass Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.51.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cryomass Technologies's Debt-to-EBITDA or its related term are showing as below:

CRYM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.71   Med: -0.13   Max: -0.02
Current: -0.19

During the past 12 years, the highest Debt-to-EBITDA Ratio of Cryomass Technologies was -0.02. The lowest was -2.71. And the median was -0.13.

CRYM's Debt-to-EBITDA is ranked worse than
100% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs CRYM: -0.19

Cryomass Technologies Debt-to-EBITDA Historical Data

The historical data trend for Cryomass Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryomass Technologies Debt-to-EBITDA Chart

Cryomass Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.07 -0.02 -0.20

Cryomass Technologies Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.09 -0.35 -0.10 -0.51

Competitive Comparison of Cryomass Technologies's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Cryomass Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryomass Technologies's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cryomass Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cryomass Technologies's Debt-to-EBITDA falls into.



Cryomass Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cryomass Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 2) / -10.135
=-0.20

Cryomass Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.23 + 2.43) / -5.256
=-0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Cryomass Technologies  (OTCPK:CRYM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Cryomass Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cryomass Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryomass Technologies (Cryomass Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1001 Bannock Street, Suite 612, Denver, CO, USA, 80204
Cryomass Technologies Inc designs, manufactures, and licenses field-mobile equipment for the handling of harvested cannabis, hemp, and other high-value plant material. The company owns patented technology that utilizes liquid nitrogen to fully separate, collect and protect the high-value compounds from the harvested plant. The company's offerings include refinement systems and monitoring and control systems.
Executives
Philip Blair Mullin officer: Chief Financial Officer 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Christian Noel director, officer: Chief Executive Officer 3531 SOUTH LOGAN ST. SUITE D-357, ENGLEWOOD CO 80113
Patricia Izabel Kovacevic officer: GC, Corp Secy, and Head of EA 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Delon Hannes Human director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Mark Radke director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Mario Gobbo director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113